Radiologix slides in 2Q
Service fees fell 9.1% in the second quarter for Radiologix, a national provider of diagnostic imaging services, to $65 million versus $71.5 million for the second quarter ended June 30. The drop was due primarily to reduced patient volume related to
Service fees fell 9.1% in the second quarter for Radiologix, a national provider of diagnostic imaging services, to $65 million versus $71.5 million for the second quarter ended June 30. The drop was due primarily to reduced patient volume related to increased competition in key markets. The numbers were up about 1%, however, compared with the previous quarter, during which Radiologix generated $64.4 million in service fees. The company achieved net income of $276,000 for the second quarter of 2003, compared with net income of $4.8 million for the previous year period and a net loss of $4.6 million for first quarter 2003. Company executives view the sequential improvement as evidence of stabilization in Radiologix' core business. Net income improved partly as a result of cost-cutting measures.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
